Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
Inv. presentation
Eloxx Pharmaceuticals, Inc. (ELOX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Presentation of Eloxx Pharmaceuticals, Inc."
08/14/2023 8-K Quarterly results
Docs: "Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update"
08/03/2023 8-K Other Events  Interactive Data
07/13/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Slides from KOL Day"
06/06/2023 8-K Other Events  Interactive Data
05/24/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statement...
Docs: "SALES AGREEMENT",
"Company”), in connection with the sale through Oppenheimer & Co. Inc., as sales agent , from time to time by the Company of shares of common stock, $0.01 par value per share, having an aggregate offering price of up to $50 million pursuant to a registration statement on Form S-3 under the Securities Act of 1933, as amended (the “Act"
04/14/2023 8-K Quarterly results
03/09/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
12/01/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
10/14/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
09/15/2022 8-K Investor presentation
Docs: "Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients",
"Presentation of Eloxx Pharmaceuticals, Inc."
08/15/2022 8-K Quarterly results
07/15/2022 8-K Quarterly results
07/05/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/04/2022 8-K Quarterly results
Docs: "Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update"
11/17/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients",
"RARE Thinking for RARE Solutions Topline ELX"
11/09/2021 8-K Quarterly results
Docs: "Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update"
10/05/2021 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...
09/30/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement, by and between Eloxx Pharmaceuticals, Inc. and SVB Leerink, LLC",
"Opinion of Latham & Watkins LLP",
"Consent of Moody, Famiglietti & Andronico, LLP, Independent Registered Public Accounting Firm"
09/13/2021 8-K Quarterly results
08/20/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/16/2021 8-K Quarterly results
Docs: "Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update"
07/16/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/06/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AGREEMENT AND GENERAL RELEASE Eloxx Pharmaceuticals, Inc. and Neil Belloff agree to the following. 1. Transition Period . The period between June 30, 2021, and the Termination Date will be a “ Transition Period ,” during which the following will apply: Executive will devote his full-time efforts to his responsibilities as the Chief Operating Officer, General Counsel and Corporate Secretary of the Company and its subsidiary Eloxx Pharmaceuticals, Ltd. and to transitioning his responsibilities to others and will assist the Company in its search for and onboarding of any successor. Executive will continue to be paid his Base Salary and to participate in the Company’ s benefit plans and programs. Executive’ s “ Termination Date ” is anticipated to be August 25, 2021, unless accelerated as foll..."
06/16/2021 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-228430 on Form S-3 and Registration Statement Nos. 333-254201, 333-236952, 333-224860, 333-222499, and 333-201891 on Form S-8 of our report dated June 16, 2021, relating to the financial statements of Zikani Therapeutics, Inc. for the years ended December 31, 2020 and 2019, appearing in this current report on Form 8-K/A of Eloxx Pharmaceuticals, Inc. /s/ Moody, Famiglietti & Andronico, LLP",
"Independent Auditors’ Report",
"ZIKANI THERAPEUTICS, INC. Index to Unaudited Interim Condensed Financial Statements CONDENSED FINANCIAL STATEMENTS CONDENSED BALANCE SHEET 2 CONDENSED STATEMENT OF OPERATIONS 3 CONDENSED STATEMENT OF CASH FLOWS 4 CONDENSED STATEMENT OF CHANGES IN CONVERTIBLE PREFERRRED STOCK AND STOCKHOLDERS’ DEFICIT 5 NOTES TO FINANCIAL STATEMENTS 6 ZIKANI THERAPEUTICS, INC. UNAUDITED CONDENSED BALANCE SHEET",
"UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION"
05/27/2021 8-K Quarterly results
05/19/2021 8-K Quarterly results
05/18/2021 8-K Quarterly results
05/18/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy